4L9Q

X-ray study of human serum albumin complexed with teniposide

Experimental procedure

Experimental method	SINGLE WAVELENGTH
Source type	ROTATING ANODE
Source details	RIGAKU RU300
Temperature [K]	100
Detector technology	IMAGE PLATE
Collection date	2003-01-01
Detector	RIGAKU RAXIS IV
Wavelength(s)	1.5418
Spacegroup name	P 1
Unit cell lengths	56.353, 59.588, 95.539
Unit cell angles	73.17, 83.45, 73.93

Refinement procedure

Resolution	29.662 - 2.700
R-factor	0.1901
Rwork	0.187
R-free	0.24290
Structure solution method	MOLECULAR REPLACEMENT
Starting model (for MR)	HUMAN SERUM ALBUMIN
RMSD bond length	0.010
RMSD bond angle	1.426
Data reduction software	DENZO
Data scaling software	SCALEPACK
Phasing software	MERLOT
Refinement software	PHENIX (1.8.2_1309)

Data quality characteristics

	Overall	Inner shell	Outer shell
Low resolution limit [Å]	30.000	30.000	2.800
High resolution limit [Å]	2.700	5.800	2.700
Rmerge	0.098	0.045	0.444
Number of reflections	30399
<I/σ(I)>	10.6
Completeness [%]	97.0	98.1	95.4

Crystallization Conditions

crystal ID	method	pH	temperature	details
1	VAPOR DIFFUSION, SITTING DROP	7.5	293	PEG 3350, POTASSIUM PHOSPHATE, Crystals of the complexes were obtained by standard vapor equilibration methods with conditions optimized by screens varying protein concentration, pH, drug molar ratios, centered on the original crystallization hit using protocols described previously for the monoclinic [Carter, et al., Eur. J. Biochemistry (1994) 226: 1049-1052] and triclinic [Sugo, et al., Protein Eng (1999) 12: 439-446] crystal forms., pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K